SY-009 / Yabao Pharma, Eli Lilly - LARVOL DELTA

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus. (PubMed, Front Endocrinol (Lausanne)) - P1 | "SY-009 caused a series of postprandial plasma metabolite changes in patients with T2DM, especially significant changes in the bile acid profile, which provides a new perspective on the mechanism by which SY-009 lowers blood glucose. https://www.clinicaltrials.gov, identifier NCT04345107."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus. (PubMed, Eur J Pharm Sci) - P1 | "Plasma exposure of SY-009 and its metabolites was fairly low in T2DM patients at doses of 1.0-4.0 mg. SY-009 reduced postprandial glucose, C-peptide, and insulin levels, showing relative safety and tolerability in the dose range of 1.0-4.0 mg."

Clinical • Journal • P1 data • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

Plastic Evolution Characterization for 304 Stainless Steel by CQN_Chen Model under the Proportional Loading. (PubMed, Materials (Basel)) - "The Hill48, SY2009 and CQN functions are used as the comparison to evaluate the accuracy of the CQN_Chen function in characterizing plastic evolution...Simultaneously, the CQN_Chen model has the capacity to adjust the yield surface shape between uniaxial tension and equibiaxial tension. The CQN_Chen model is recommended to characterize plastic evolving behavior under uniaxial tension along different directions and equibiaxial tension."

Journal

SY009. Adding Value by Subtraction: De-escalating to Deliver Good-Value Thyroid Care (ENDO 2023) - "DESCRIPTION In the care of patients, it is important to "first do no harm." Yet overdiagnosis and overtreatment are common in the medical field, placing patients at risk of harm. In this session, expert thyroidologists will define low-value care and discuss strategies for de-implementation."

Solid Tumor

Protein interaction, cytotoxic, transcriptomic and proteomic responses to structurally distinct EPAC1 activators in HUVECs. (PubMed, Sci Rep) - "This was soon followed by the identification of the I942 analogues, PW0381, PW0521 and PWO577 and a series of benzofuran oxoacetic acid EPAC1 activators, SY006, SY007 and SY009. Together these results demonstrate the utility of structurally distinct, specific and non-toxic EPAC1 activators. Future modifications will be aimed at eliminating the few noted off-target effects."

Journal • CCL2 • ICAM1 • IL6 • IL6ST • JAK3 • MMP1 • SOCS3 • STAT3

(SY009) Advances in the Fundamental Understanding and Therapeutic Applications of Cilia (ENDO 2022) - No abstract available

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

(SY009) Symposium Advances in the Fundamental Understanding and Therapeutic Applications of Cilia (ENDO 2022) - No abstract available

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Recruiting ➔ Completed

Trial completion • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Clinical • New P1 trial